AngioDynamics GAAP EPS of -$0.07 beats by $0.11, revenue of $86.61M beats by $6.37M

Seeking Alpha · 2026-07-14

AngioDynamics press release ( ANGO ): Q4 GAAP EPS of -$0.07 beats by $0.11 . Revenue of $86.61M (+8.0% Y/Y) beats by $6.37M . FY26 revenue consensus of $314.02M, EPS consensus of -$0.20 Guidance Metric Guidance (As of July 14, 2026) Net Sales $336.0M - $341.0M Med Tech Net Sales Growth 12% – 15% Med Device Net Sales Growth Flat Gross Margin 54% – 55% Adjusted EBITDA $13.0M - $16.0M Adjusted EPS ($0.29) – ($0.24) AngioDynamics, Inc. (ANGO) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Slideshow Seeking Alpha’s Quant Rating on AngioDynamics Historical earnings data for AngioDynamics

AI 시장 분석

AngioDynamics reported a Q4 GAAP EPS of -$0.07, beating market expectations by $0.11, while revenue rose 8.0% year-over-year to $86.61 million, exceeding estimates by $6.37 million. The company provided FY2026 revenue guidance of $336 million to $341 million, signaling robust growth. This strong performance suggests that revenue growth in the medical technology sector and efficient cost management are key drivers, providing a positive signal to investors.

상승 영향

Biotech — ANGO's 8% year-over-year revenue growth and significant beat against market estimates are expected to improve investor sentiment across the medical device and technology sectors. In particular, the strong revenue growth guidance of 12-15% suggests the potential for market share expansion.

DYAX 전담 분석

AngioDynamics demonstrated significant operational progress in the fourth quarter. The combination of beating top and bottom-line estimates highlights the company's improved execution.

The forward-looking guidance for fiscal 2026 reflects confidence in its core portfolio and market strategy, likely positioning the stock favorably for long-term growth.

AI가 생성한 분석으로 투자 자문이 아닙니다.

DYAX Investor Sentiment

Bullish (Long) 62% · Bearish (Short) 38%

419 participants

Related News

원문 보기 — Seeking Alpha